Kidney patients get first look at new obesity drug

NCT ID NCT07443059

Recruiting now Knowledge-focused Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of Zovaglutide (ZT002), an experimental drug for overweight and obesity, in 40 adults with varying levels of kidney function. Researchers will measure how the drug moves through the body and check for side effects. The goal is to understand if kidney problems change how the drug works, not to treat kidney disease or cause weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zovaglutide (ZT002 injection)
What this could lead to: If successful, this could help determine safe dosing of Zovaglutide for people with kidney problems who are overweight or obese.
What could go wrong: This is a very early Phase 1 study with only 40 participants. It focuses on drug levels and safety, not on weight loss or kidney improvement. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT , OBESITY

Contacts and locations

Locations

Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, 250014, China
The First Affiliated Hospital Of Shandong First Medical Unversity
RECRUITING

Jinan, Shandong, 250014, China
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITING

Xiamen, Fujian, 361003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.